Page 2 - Decision Resource Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Decision resource group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Decision Resource Group Today - Breaking & Trending Today

GoodRx purchases fellow prescription price transparency company RxSaver for $50M

Photo: ljubaphoto/Getty Images
GoodRx, a company best known for its price transparency tools, snapped up RxSaver, a startup that gives users discounts on prescription medicines for a cool $50 million, Bloomberg first reported.
You know, the RxSaver acquisition allows us to extend our reach and prescription transactions by adding a small consumer base and a brand that s known and resonates with a subset of consumers. The company has a talented team and knows the prescription transaction space well. We think they ll be highly complementary to GoodRx, Karsten Voermann, GoodRx s chief financial officer, said during the earnings call.
RxSaver has some similar functions to GoodRx. Users are able to search for prescription drugs and compare prices at local pharmacies. The site also offers free coupons to bring to a pharmacy. According to the company s webpage, the savings can be up to 85% off. ....

Karsten Voermann , Decision Resource Group , Vericast Corp , Amazon Pharmacy , Amazon Prime , Friday May , Goodrx Care , Amazon Care , முடிவு வள குழு , அமேசான் மருந்தகம் , அமேசான் ப்ரைம் , வெள்ளி இருக்கலாம் , அமேசான் பராமரிப்பு ,

LORBRENA (lorlatinib) sNDA in Previously Untreated ALK-Positive Lung Cancer Accepted for Priority Review by U.S. FDA

Posted on
8403
Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for LORBRENA
® (lorlatinib) as a first-line treatment for people with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC). The sNDA is based on data from the pivotal CROWN study and is being reviewed by the FDA under its Real-Time Oncology Review (RTOR) pilot program. The Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA is in April 2021.
LORBRENA is a third-generation ALK inhibitor specifically developed to inhibit the most common tumor mutations that drive resistance to current medications and to address brain metastases. Up to 40% of people with ALK-positive lung cancer present with brain metastases. ....

United States , United Kingdom , South Korea , Steven Danehy , Chris Boshoff , Bryan Dunn , Peterss Alectinib , Kantar Health , Decision Resource Group , Time Oncology Review Pilot Program , Pfizer Inc , International Agency For Research On Cancer , European Union , Virtual Congress , American Cancer Society , Drug Administration , World Health Organization , Pfizer Global Product Development , Exchange Commission , European Society For Medical Oncology , Priority Review , New Drug Application , Real Time Oncology Review , Prescription Drug User Fee Act , Chief Development Officer , Pfizer Global Product ,

LORBRENA® (lorlatinib) sNDA in Previously Untreated ALK-Positive Lung Cancer Accepted for Priority Review by U.S. FDA

Press release content from Business Wire. The AP news staff was not involved in its creation.
LORBRENA® (lorlatinib) sNDA in Previously Untreated ALK-Positive Lung Cancer Accepted for Priority Review by U.S. FDA
December 28, 2020 GMT
NEW YORK (BUSINESS WIRE) Dec 28, 2020
Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for LORBRENA ® (lorlatinib) as a first-line treatment for people with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC). The sNDA is based on data from the pivotal CROWN study and is being reviewed by the FDA under its Real-Time Oncology Review (RTOR) pilot program. The Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA is in April 2021. ....

United States , United Kingdom , South Korea , Steven Danehy , Chris Boshoff , Bryan Dunn , Peterss Alectinib , Kantar Health , Decision Resource Group , Time Oncology Review Pilot Program , Pfizer Inc , International Agency For Research On Cancer , European Union , Virtual Congress , American Cancer Society , Drug Administration , World Health Organization , Pfizer Global Product Development , Exchange Commission , European Society For Medical Oncology , Priority Review , New Drug Application , Real Time Oncology Review , Prescription Drug User Fee Act , Chief Development Officer , Pfizer Global Product ,